Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
- Lise-Meitner-Str. 30
- Freising , 85354
XL-protein is a privately owned German biotech company commercializing the PASylation technology, which allows the extension of the plasma half-life of biopharmaceuticals. XL-protein focuses on the preclinical and clinical development of PASylated proteins in several disease areas. Its goal is to provide improved second-generation biopharmaceuticals allowing less frequent and lower dosing together with better tolerability, making treatment cheaper and supporting patient compliance and safety.